Citigroup Issues Positive Forecast for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its price target raised by Citigroup from $77.00 to $84.00 in a research note published on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the medical device company’s stock.

Several other equities research analysts also recently commented on DXCM. Leerink Partners reissued an “outperform” rating and issued a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Barclays restated an “underweight” rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Canaccord Genuity Group set a $95.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.50.

DexCom Stock Performance

DXCM opened at $66.31 on Wednesday. DexCom has a 52-week low of $54.11 and a 52-week high of $89.98. The firm has a market capitalization of $25.52 billion, a PE ratio of 31.58, a PEG ratio of 1.32 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The business’s 50-day simple moving average is $70.73 and its 200 day simple moving average is $68.55.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 earnings per share. As a group, sell-side analysts expect that DexCom will post 2.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DexCom

A number of large investors have recently added to or reduced their stakes in DXCM. Brighton Jones LLC increased its holdings in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth boosted its holdings in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares during the period. Finally, AE Wealth Management LLC grew its stake in DexCom by 50.5% in the 2nd quarter. AE Wealth Management LLC now owns 24,701 shares of the medical device company’s stock valued at $2,156,000 after buying an additional 8,283 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Citigroup raised its price target on DXCM from $77 to $84 and kept a “buy” rating — a notable analyst upgrade that implies roughly 27% upside from the current price. Citigroup price target raise (Benzinga)
• Positive Sentiment: BTIG issued a “Buy” rating on DexCom, adding to the recent wave of buy-side analyst support. BTIG Buy Rating (American Banking News)
• Positive Sentiment: DexCom presented clinical outcomes and outlined its product roadmap at the ATTD 2026 conference in Barcelona — product pipeline/detail disclosures are typically viewed positively for long-term growth prospects. ATTD 2026 presentation (Business Wire)
• Positive Sentiment: The Motley Fool included DexCom among long-term growth stock picks, reinforcing a buy-and-hold narrative for investors focused on multi-year gains. Long-term growth stock mention (Fool)
• Neutral Sentiment: Benzinga ran a roundup of 12 analyst reviews on DexCom that provides mixed analyst perspectives and consensus context — useful for gauging sentiment but not a single-direction catalyst. Analyst reviews roundup (Benzinga)
• Neutral Sentiment: MarketWatch noted DexCom outperformed some competitors on the day despite broader losses — a relative-strength datapoint but not a direct directional driver. Relative performance note (MarketWatch)
• Neutral Sentiment: Reported spikes in short interest appear in the data feeds, but the published entries show zero shares / NaN changes — this looks like a data error and should not be treated as confirmed bearish pressure until clarified by exchanges. (Data entry from March filings)

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.